Astrazeneca plc ADR (NASDAQ:AZN) has a beta value of 0.49 and has seen 15.25 million shares traded in the last trading session. The company, currently valued at $205.48B, closed the last trade at $66.27 per share which meant it lost -$5.16 on the day or -7.22% during that session. The AZN stock price is -32.31% off its 52-week high price of $87.68 and 8.75% above the 52-week low of $60.47. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.47 million shares traded. The 3-month trading volume is 4.26 million shares.
The consensus among analysts is that Astrazeneca plc ADR (AZN) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 10 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Sporting -7.22% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the AZN stock price touched $66.27 or saw a rise of 10.06%. Year-to-date, Astrazeneca plc ADR shares have moved -1.60%, while the 5-day performance has seen it change -11.90%. Over the past 30 days, the shares of Astrazeneca plc ADR (NASDAQ:AZN) have changed -13.79%. Short interest in the company has seen 4.03 million shares shorted with days to cover at 1.14.
Wall Street analysts have a consensus price target for the stock at $85, which means that the shares’ value could jump 22.04% from current levels. The projected low price target is $79.0 while the price target rests at a high of $89.0. In that case, then, we find that the current price level is -34.3% off the targeted high while a plunge would see the stock gain -19.21% from current levels.
Astrazeneca plc ADR (AZN) estimates and forecasts
Figures show that Astrazeneca plc ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -13.17% over the past 6 months, with this year growth rate of 11.85%, compared to 8.20% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 17.72% over the past 5 years. Earnings growth for 2024 is a modest 12.26% while over the next 5 years, the company’s earnings are expected to increase by 12.00%.
AZN Dividends
Astrazeneca plc ADR is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.49 at a share yield of 2.24%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 2.36%.
Astrazeneca plc ADR (NASDAQ:AZN)’s Major holders
Insiders own 0.01% of the company shares, while shares held by institutions stand at 17.08% with a share float percentage of 17.08%. Investors are also buoyed by the number of investors in a company, with Astrazeneca plc ADR having a total of 1469.0 institutions that hold shares in the company. The top two institutional holders are PRICE T ROWE ASSOCIATES INC /MD/ with over 64.94 million shares worth more than $5.06 billion. As of 2024-06-30, PRICE T ROWE ASSOCIATES INC /MD/ held 2.0962% of shares outstanding.
The other major institutional holder is PRIMECAP MANAGEMENT CO/CA/, with the holding of over 42.6 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.32 billion and represent 1.375% of shares outstanding.
